NEW YORK, April 7 (GenomeWeb News) - Invitrogen and Agilent Technologies today announced a two-year agreement to co-market the PathAlert System, a technology that combines Invitrogen reagents and Agilent's 2100 bioanalyzer or 5100 Automated Lab-on-a-Chip platforms.
Invitrogen will distribute the PCR-based technology, which as been successfully evaluated by the US Department of Defense and the Environmental Protection Agency, the companies said.
The news comes one day after the US government held a hearing to discuss ways in which the different agencies responsible for overseeing pathogen detection can work together more effectively. As reported by GenomeWeb News publication Pharmacogenomics Reporter this week, the outcome of this hearing could benefit companies developing pathogen-detection technologies, such as Cepheid, CombiMatrix, and now Invitrogen and Agilent.
By testing samples collected from the air, food, and water, the system may be used to detect infectious agents such as Bacillus anthracis, which causes anthrax; Yersinia pestis, which causes plague; Vaccinia, which causes smallpox simulant; and Francisella tularensis, which causes tularemia.
Financial details of the collaboration were not disclosed.